Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Mar;18(1):51-54.
doi: 10.1007/s40268-017-0218-4.

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects

Affiliations
Clinical Trial

Bioavailability of Orally Administered Des-Aspartate-Angiotensin I in Human Subjects

Kok-Onn Lee et al. Drugs R D. 2018 Mar.

Abstract

In an earlier single-dose escalation study to evaluate the safety and pharmacokinetics of orally administered des-aspartate-angiotensin I (DAA-I) in healthy subjects, the plasma level of DAA-I could not be determined because DAA-I is rapidly degraded in the circulation. The present study investigated the oral bioavailability of DAA-I by measuring the prostaglandin E2 metabolite (PGEM) in the plasma samples of the same trial. PGEM is a stable derivative of PGE2, which has been shown to be a biomarker of DAA-I. The data show that plasma from two of the three subjects who were orally administered the efficacious preclinical dose of 0.70 mg/kg DAA-I exhibited a significant PGEM peak at 5-6 h postdose. Plasma of subjects who were administered 0.08 and 1.5 mg/kg DAA-I, the subefficacious and two-times efficacious dose, respectively, did not exhibit a similar PGEM peak. This observation is concordant with the known in vivo actions of DAA-I, especially its hypoglycemic action where maximum efficacy occurred at a dose of 0.7 mg/kg, and decreased to nil at the two-times efficacious dose. The onset of the PGEM peak at 5-6 h postdose was closed to the 4-h onset of absorption of [C14]DAA-I seen in preclinical rat studies, albeit the absorption kinetics between rodents and humans are not identical. The occurrence of polymorphism of enzymes involved in the formation and degradation of PGE2 is common, and this has been attributed to contributing to the variation in response, onset and peak PGEM observed among the three subjects who were administered the efficacious dose.

PubMed Disclaimer

Conflict of interest statement

Kok-Onn Lee, Edmund Feng Tian, Martin Hui Cai, Hong Wang, Yiong-Huak Chan and Meng-Kwoon Sim have no conflicts of interest with regard to financial sponsorship or governmental guidelines on the publication of this article.

Figures

Fig. 1
Fig. 1
Plasma PGEM concentrations. A5, B2, B6, C2 and C5 were placebo samples, and samples in the upper, middle and lower plots were from subjects who were administered 0.08, 0.70, and 1.5 mg/kg DAA-I, respectively. * Indicates significantly greater than the corresponding values of B1, B2, B4 and B6 (p < 0.01), # indicates significantly greater than the corresponding values of B2 and B6 (p < 0.01)

References

    1. Sim MK. Des-aspartate-angiotensin I, a novel angiotensin AT1 receptor drug. Eur J Pharmacol. 2015;760:36-1. doi: 10.1016/j.ejphar.2015.04.004. - DOI - PubMed
    1. Sim MK. The use of des-aspartate-angiotensin I in inflammation related pathologies and diseases. Patent Cooperation Treaty, International Application No. PCT/SG2011/000204, 8 Jun 2011.
    1. Wang H, Sethi G, Loke WK, Sim MK. Des-aspartate-angiotensin I attenuates mortality of mice exposed to gamma radiation via a novel mechanism of action. PLoS One. 2015;10(9):e0138009. doi: 10.1371/journal.pone.0138009. - DOI - PMC - PubMed
    1. Wen Q, Lee KO, Sim SZ, Xu XG, Sim MK. Des-aspartate-angiotensin I causes specific release of PGE2 and PGI2 in HUVEC via the angiotensin AT1 receptor and biased agonism. Eur J Pharmacol. 2015;768:173–181. doi: 10.1016/j.ejphar.2015.10.051. - DOI - PubMed
    1. Gayes RP, Szidon JP, Opari S. In vivo and in vitro conversion of des-1-Asp angiotensin I to angiotensin III. Biochem Pharmacol. 1978;27:2871–2877. doi: 10.1016/0006-2952(78)90203-4. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources